This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: STAAR Surgical’s CEO is stepping down after the implantable eye lens manufacturer opposed a $1.6 billion takeover. Encouraged by activist investor Broadwood Partners, STAAR shareholders rejected Alcon’s $1.6 billion offer last week. Thursday, STAAR revealed a cooperation agreement with Broadwood that has reshaped its board. Stephen Farrell has left th ...

Core Insights - The JPM Health Conference highlighted a shift in focus among major medical device companies from investment narratives to growth execution, emphasizing the importance of mergers and acquisitions, AI integration, and organizational restructuring for future growth [2][4]. Medtronic - Medtronic's leadership emphasized a transition to a "growth execution phase," with a focus on accelerating growth through existing technologies and strategic acquisitions, particularly smaller tuck-in acquisitions [6][7]. - The company plans to launch its Hugo surgical robot system in the U.S. in 2026, targeting soft tissue surgery as a key growth area, and sees significant market potential in cardiac electrophysiology and renal denervation [7][8]. - Medtronic aims for mid-to-high single-digit revenue growth in 2026, driven by advancements in ASC penetration and AI-enabled surgical planning [8]. Boston Scientific - Boston Scientific reported over 10% revenue growth for three consecutive years, driven by core products like PFA and WATCHMAN, with a focus on maintaining high growth in the electrophysiology market [10][11]. - The company aims to enhance the overall adoption of arrhythmia treatments and expand its product offerings, including the FARAPOINT catheter, to new indications [11]. - Boston Scientific's growth strategy includes targeting outpatient surgical centers and advancing its clinical pipeline with new innovations [11]. Stryker - Stryker's CEO highlighted the importance of mergers and acquisitions, particularly in orthopedics and neurology, while focusing on enhancing the Mako robotic platform [12][14]. - The company expects to achieve 7%-9% revenue growth in 2026, with a strong emphasis on outpatient surgical centers as a significant growth driver [14]. Johnson & Johnson - Johnson & Johnson's CEO indicated a return to fundamentals, with a focus on execution and long-term growth, planning to invest approximately $55 billion in new facilities and R&D, particularly in MedTech [15][17]. - The company is preparing for regulatory milestones for its Ottava surgical robot system, with significant contributions expected post-2028 [17][18]. - J&J's strategy includes strategic investments in robotic systems to enhance its outpatient surgical capabilities [18]. Intuitive Surgical - Intuitive Surgical's focus remains on expanding its da Vinci system and integrating AI functionalities to improve surgical efficiency [19][20]. - The company anticipates a competitive landscape in soft tissue robotics but believes its established ecosystem provides a competitive advantage [20]. - Intuitive expects revenue growth of 12%-15% in 2026, driven by increased surgical volumes and international market expansion [20]. Alcon - Alcon is committed to innovation in eye health, focusing on surgical and vision care segments, with a significant emphasis on enhancing operational efficiency [22][23]. - The company aims to launch 10-15 new products over the next two years, maintaining an annual R&D investment of around $1 billion [23]. Abbott - Abbott's strategy emphasizes stable execution, particularly in diabetes management, with plans to expand the FreeStyle Libre system's applications [24]. - The company expects 8%-10% revenue growth in its MedTech business for 2026, focusing on internal innovation and operational efficiency [24]. GE Healthcare - GE Healthcare is shifting its AI capabilities towards standalone software tools, emphasizing the commercialization of AI in imaging [25]. - The company plans to simplify its product offerings to enhance customer experience and reduce internal costs, aiming for organic growth through advanced imaging technologies [25]. Illumina - Illumina's growth strategy focuses on sequencing, multi-omics, and scaling services, with a strong emphasis on partnerships to accelerate drug development [29][30]. - The company aims to maintain a balanced approach between innovation investment and shareholder returns, with a positive outlook for the Chinese market [30]. Edwards Lifesciences - Edwards Lifesciences is focused on structural heart disease, with a commitment to innovation in TAVR and TMTT platforms, expecting 8%-10% sales growth [33][34]. - The company is addressing regulatory challenges while continuing to invest in breakthrough therapies and expanding market access [34]. Jabil - Jabil's CEO discussed the company's transformation and focus on integrating recent acquisitions, with a strategic emphasis on improving sales efficiency in the U.S. market [36][37]. - The company plans to launch new products and leverage AI technology to enhance its offerings in the orthopedic sector [37]. Conclusion - The overall sentiment from the JPM26 conference indicates that major medical device companies are prioritizing alignment of products, organizational structure, and capital utilization to drive growth, rather than focusing solely on new technologies [40].

PresentationDavid EndicottCEO & Director All right. Thanks. Let me start with just a little bit of introduction. If you're not familiar with Alcon, we are an eye care company. We do a little bit of everything in eye care. We have the pleasurable purpose of dealing with what is, generally speaking, one of the most severe concerns of elderly folks. After memory loss, vision loss is the #1 concern of folks as they age. And we work on refractive error, we work on presbyopia, dry eye, if it's in the eye or if it ...

Alcon (NYSE:ALC) FY Conference January 13, 2026 11:15 AM ET Company ParticipantsDavid Endicott - CEODavid Adlington - Head of the European Medtech and Services ResearchNone - Video NarratorTim Stonesifer - SVP and CFOConference Call ParticipantsNone - AnalystDavid AdlingtonGood morning, everybody. Welcome to day two of the JPMorgan Conference. I'm David Adlington. I head up the European Medtech and Services Research Team in London for JP. It's my pleasure to introduce, we've got David and Tim on stage. Over ...

J.P. Morgan Healthcare Conference David J. Endicott Chief Executive Officer January 13th, 2026 Safe harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," ...

Core Insights - Alcon Inc. is a significant player in the ophthalmic industry, focusing on eye care products and surgical equipment, competing with major companies like Johnson & Johnson Vision and Bausch + Lomb [1] - Stifel Nicolaus has set a price target of $80 for Alcon, with the stock currently trading at $80.62, reflecting a slight decrease of approximately 0.77% from the target price [1][6] Company Developments - Alcon has terminated its agreement to acquire STAAR Surgical due to the failure to secure necessary stockholder votes, which may impact its market position and future growth strategies [2][6] - STAAR Surgical will continue as an independent publicly traded company, with a focus on profitable sales growth and enhancing distribution efficiencies, particularly expanding the use of its EVO ICL technology globally [3][6] Market Performance - Alcon's stock is currently priced at $80.62, showing a decrease of 0.49% or $0.40, with fluctuations between $79.68 and $81.11 today, and a 52-week high of $99.20 and a low of $71.55 [5] - Alcon's market capitalization is approximately $39.87 billion, with a trading volume of 1,128,034 shares [5]

GENEVA--(BUSINESS WIRE)--Alcon Terminates Agreement to Acquire STAAR Surgical. ...

STAAR Surgical Company (NASDAQ:STAA) announced Tuesday that it did not receive the necessary stockholder votes to approve the merger agreement with Alcon Inc. (NYSE:ALC) at the Special Meeting of Stockholders.STAAR intends to terminate its merger agreement with Alcon.No termination fee will be payable by either party, and STAAR will remain a standalone publicly traded company.Stephen Farrell, CEO of STAAR, said, “…In the short term, we will continue to prioritize profitable sales growth while we drive effic ...

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates ("Broadwood†or "we†), which together own 30.2% of the outstanding common stock of STAAR Surgical Company ("STAAR†or the "Company†) (NASDAQ: STAA), commented on the results of the Special Meeting of Shareholders (the "Special Meeting†) that was held earlier today in connection with the proposed acquisition of STAAR by Alcon Inc. ("Alcon†) (NYSE: ALC). Based on preliminary results, shareholders voted decisively to reject the. ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. O. ...